Drugs / T-DXd
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06174987 | Jan 2024 → Aug 2026 overdue | cancer of unknown primary site, metastatic malignant neoplasm | Daiichi Sankyo | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2024-05-22 | AstraZeneca | Results AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024 astrazeneca.com ↗
A clinically meaningful PFS improvement was also seen in patients with HER2-ultralow expression. |
| 2023-10-23 | AstraZeneca | Results Enhertu demonstrated clinically meaningful survival across multiple HER2-expressing advanced solid tumours in DESTINY-PanTumor02 Phase II trial astrazeneca.com ↗
AstraZeneca and Daiichi Sankyo’s Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population |
| 2023-04-14 | AstraZeneca | Results AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR astrazeneca.com ↗
Combination of T-DXd with the irreversible pan-HER TKI afatinib drives combination benefit in HER2-low gastric and lung tumours |
| 2022-11-22 | AstraZeneca | Results AstraZeneca aims to redefine breast cancer care with new data across the treatment spectrum at SABCS 2022 astrazeneca.com ↗
Updated results from the DESTINY-Breast03 Phase III trial of Enhertu versus trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer previously treated with trastuzumab and a taxane will be presented, including updated progression-free survival (PFS) data and overall survival (OS) results. |
| 2022-11-14 | AstraZeneca | Regulatory Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive advanced gastric cancer astrazeneca.com ↗ |
| 2022-05-23 | AstraZeneca | Results AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022 astrazeneca.com ↗
The results from DESTINY-Breast04 support the potential for Enhertu to redefine the classification and treatment of breast cancer across the spectrum of HER2 expression. |
| 2022-03-28 | AstraZeneca | Results AstraZeneca aims to transform the oncology treatment landscape with diverse early pipeline and novel combinations at AACR astrazeneca.com ↗
Preclinical data will be presented that support this hypothesis showing the activity of Enhertu (trastuzumab deruxtecan) in combination with DDR agents including PARP1-selective inhibitors. |
| 2022-01-13 | AstraZeneca | Results AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data at ASCO GI and GU astrazeneca.com ↗
At ASCO GI, data will include an encore presentation of the OS results of the DESTINY-Gastric01 Phase II trial of Enhertu (trastuzumab deruxtecan) in HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma (GEJA), and initial results from the DESTINY-Gastric03 Phase Ib/II trial in HER2-positive gastric cancer and GEJA. |
| 2021-09-02 | AstraZeneca | Results AstraZeneca lung and breast cancer data at WCLC and ESMO 2021 underscore ambition to revolutionise outcomes for patients astrazeneca.com ↗
At ESMO, a Presidential Symposium will present the results from the DESTINY-Breast03 Phase III trial demonstrating the potentially transformative impact of Enhertu (trastuzumab deruxtecan) for patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-DXd | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06174987 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT06174987 ↗ |